SRRK — Scholar Rock Holding Corp

Scholar Rock Holding Corp (SRRK) is a biotechnology company listed on NASDAQ. It is led by David L. Hallal, based in 301 Binney Street, Cambridge, MA, United States, 02142, with about 128 employees. Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Latest reported SRRK revenue for 2025-09-30 was $0. Net income was -$287.0M. SRRK currently screens at market cap $3.42B.

Use this SRRK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SRRK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SRRK SEC filings page. Lician reads the product cache first so this HTML stays unique to Scholar Rock Holding Corp even when a live quote feed is slow.